Focal Cerebral Embolic Ischemia Model
Objective: To investigate the effects of recombinant human VEGF 165 on angiogenesis, blood-brain barrier leakage, and neurological recovery in a rat model of focal cerebral embolic ischemia
This is a Focal Cerebral Embolic Ischemia Model protocol using rat as the model organism. The procedure involves 7 procedural steps, 2 equipment items, 1 materials. Extracted from a 2000 paper published in Journal of Clinical Investigation.
Model and subjects
rat • Not specified • unknown • Not specified • Not specified
Study window
~98 hours hands-on
Core workflow
Establish focal cerebral embolic ischemia model • Early postischemic administration of rhVEGF 165 • Late postischemic administration of rhVEGF 165
Primary readouts
- Angiogenesis in ischemic penumbra
- Functional neurological recovery
- Blood-brain barrier leakage
- Hemorrhagic transformation
Key equipment and reagents
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Establish focal cerebral embolic ischemia model
Create a rat model of focal cerebral embolic ischemia
Note: This is the baseline ischemic condition in which subsequent treatments are applied
View evidence from paper
“in a rat model of focal cerebral embolic ischemia”
Early postischemic administration of rhVEGF 165
Administer recombinant human VEGF 165 to ischemic rats at 1 hour post-ischemia
Note: Early administration significantly increased BBB leakage, hemorrhagic transformation, and ischemic lesions
View evidence from paper
“early postischemic (1 hour) administration of rhVEGF 165 to ischemic rats significantly increased BBB leakage, hemorrhagic transformation, and ischemic lesions”
Late postischemic administration of rhVEGF 165
Administer recombinant human VEGF 165 to ischemic rats at 48 hours post-ischemia
Note: Late administration enhanced angiogenesis in the ischemic penumbra and significantly improved neurological recovery
View evidence from paper
“Late (48 hours) administration of rhVEGF 165 to the ischemic rats enhanced angiogenesis in the ischemic penumbra and significantly improved neurological recovery”
Measure angiogenesis using MRI and confocal microscopy
Use magnetic resonance imaging and three-dimensional laser-scanning confocal microscope to measure angiogenesis effects
Note: Measurements performed to assess vascular changes in ischemic penumbra
View evidence from paper
“Using magnetic resonance imaging (MRI), three-dimensional laser-scanning confocal microscope, and functional neurological tests, we measured the effects”
Perform functional neurological tests
Conduct functional neurological tests to assess neurological recovery and outcome
Note: Tests used to measure functional neurological outcome in treated ischemic rats
View evidence from paper
“Using magnetic resonance imaging (MRI), three-dimensional laser-scanning confocal microscope, and functional neurological tests, we measured the effects”
Assess BBB leakage and hemorrhagic transformation
Evaluate blood-brain barrier leakage and hemorrhagic transformation in ischemic brain tissue
Note: Early VEGF administration increased BBB leakage and hemorrhagic transformation; late administration did not change BBB leakage in contralateral hemisphere
View evidence from paper
“early postischemic (1 hour) administration of rhVEGF 165 to ischemic rats significantly increased BBB leakage, hemorrhagic transformation, and ischemic lesions”
Measure cerebral plasma perfusion
Assess cerebral plasma perfusion in both ischemic and contralateral hemispheres
Note: rhVEGF 165 administration did not change cerebral plasma perfusion in the contralateral hemisphere
View evidence from paper
“Administration of rhVEGF 165 to ischemic rats did not change BBB leakage and cerebral plasma perfusion in the contralateral hemisphere”